Overview
ONO-4059-10:Multicenter, placebo-controlled, randomized, double-blind, Phase 3 study in patients with steroid-resistant pemphigus
Eligibility
Inclusion Criteria:
- Patients with a diagnosis of pemphigus
- Patients with a re-increase in the pemphigus disease area index (PDAI) score before oral corticosteroid tapering to 10mg/day of prednisolone (PSL) equivalent
Exclusion Criteria:
- Patients with an active infection
- Patients with malignancy
- Patients with past history of serious allergy or anaphylaxis